Format

Send to

Choose Destination
Langenbecks Arch Surg. 2011 Oct;396(7):1077-81. doi: 10.1007/s00423-011-0835-2. Epub 2011 Aug 13.

Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned.

Author information

1
Department of General, Visceral and Transplant Surgery, Comprehensive Cancer Center, University of Tübingen, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany. ingmar.koenigsrainer@med.uni-tuebingen.de

Abstract

PURPOSE:

Peritoneal recurrence of ovarian cancer is frequent after primary surgery and chemotherapy and has poor long-term survival. De novo cytoreductive surgery is crucial with the potential to improve prognosis, especially when combined with hyperthermic intraperitoneal chemotherapy (HIPEC).

METHODS:

The sampled data of 40 consecutive patients were retrospectively analyzed. Thirty-one patients were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy.

RESULTS:

No patient was lost in the perioperative period, and the combined procedure was performed with acceptable morbidity. Colon-preserving cytoreductive surgery was associated with reduced morbidity.

CONCLUSIONS:

Patients suffering from peritoneal recurrence of ovarian cancer should be considered for radical reoperation with HIPEC in a center with expertise in multimodal therapeutic options. Organ-preserving cytoreductive surgery allows complete cytoreduction with the goal of decreasing morbidity.

PMID:
21842290
DOI:
10.1007/s00423-011-0835-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center